These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 12544490)
1. AAV-mediated gene transfer for hemophilia. High K Genet Med; 2002; 4(6 Suppl):56S-61S. PubMed ID: 12544490 [TBL] [Abstract][Full Text] [Related]
2. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia. High KA Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929 [TBL] [Abstract][Full Text] [Related]
3. AAV-mediated gene transfer for hemophilia. High KA Ann N Y Acad Sci; 2001 Dec; 953():64-74. PubMed ID: 11795424 [TBL] [Abstract][Full Text] [Related]
4. Adeno-associated virus-mediated gene transfer for hemophilia B. High KA Int J Hematol; 2002 Nov; 76(4):310-8. PubMed ID: 12463593 [TBL] [Abstract][Full Text] [Related]
5. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Manno CS; Chew AJ; Hutchison S; Larson PJ; Herzog RW; Arruda VR; Tai SJ; Ragni MV; Thompson A; Ozelo M; Couto LB; Leonard DG; Johnson FA; McClelland A; Scallan C; Skarsgard E; Flake AW; Kay MA; High KA; Glader B Blood; 2003 Apr; 101(8):2963-72. PubMed ID: 12515715 [TBL] [Abstract][Full Text] [Related]
6. AAV-mediated gene transfer for treatment of hemophilia. Wang L; Herzog RW Curr Gene Ther; 2005 Jun; 5(3):349-60. PubMed ID: 15975012 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Arruda VR; Schuettrumpf J; Herzog RW; Nichols TC; Robinson N; Lotfi Y; Mingozzi F; Xiao W; Couto LB; High KA Blood; 2004 Jan; 103(1):85-92. PubMed ID: 12969984 [TBL] [Abstract][Full Text] [Related]
8. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Sabatino DE; Lange AM; Altynova ES; Sarkar R; Zhou S; Merricks EP; Franck HG; Nichols TC; Arruda VR; Kazazian HH Mol Ther; 2011 Mar; 19(3):442-9. PubMed ID: 21081906 [TBL] [Abstract][Full Text] [Related]
10. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects. Hasbrouck NC; High KA Gene Ther; 2008 Jun; 15(11):870-5. PubMed ID: 18432276 [TBL] [Abstract][Full Text] [Related]
11. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Kay MA; Manno CS; Ragni MV; Larson PJ; Couto LB; McClelland A; Glader B; Chew AJ; Tai SJ; Herzog RW; Arruda V; Johnson F; Scallan C; Skarsgard E; Flake AW; High KA Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178 [TBL] [Abstract][Full Text] [Related]
14. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793 [TBL] [Abstract][Full Text] [Related]